Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Phone Check-Ins could prevent falls during chemo

NCT ID NCT05330104

Knowledge-focused Sponsor: Allina Health System Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested whether brief smartphone surveys can help detect early signs of fall risk in people receiving chemotherapy that can cause nerve damage. Twelve cancer patients used a mobile app to report symptoms like numbness or tingling in their legs. The goal was to see if patients would stick with the surveys and find them useful, not to treat the nerve damage itself.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Mobile Ecological Momentary Assessment (mEMA) surveys
What this could lead to
If successful, this approach could help identify patients at risk of falling early, allowing them to get rehab and continue life-saving chemotherapy.
What could go wrong
This is a very small feasibility study with only 12 participants. It does not test a treatment, only a monitoring method, so it may not lead to direct patient benefits.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

12 people

The number who actually took part.

Started

Jan 2022

Finished

Jun 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

45 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. ≥ 45 years old 2. New cancer diagnosis other than a primary brain tumor 3. A taxane and/or platinum chemotherapy agent has been prescribed as part of the treatment regimen for cancer. 4. English speaking 5. Able to see, hear, speak (with or without assistive devices) 6. Able to walk without an assistive device - for example: cane, walker, walking stick(s) at the start of cancer treatment 7. Able to provide own transportation to study visits 8. Willing and able to commit to symptom tracking three times weekly via mEMA for up to 9 months. 9. Owns a smartphone with one of the following operating system versions: iOS 8.0 - 8.4, 9.0 - 9.3, 10.0 - 10.3, 12, 13.3 or later Android 7.0 - 7.1.2, 8.0 - 8.1.0, 9, 10 or later 10. Agree to use personal smartphone to download the mEMA application and respond to application notifications. Exclusion Criteria: 1. Individuals who started their chemotherapy regimen greater than 4 weeks prior to study enrollment. 2. Individuals being treated for a primary brain tumor

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Chemotherapy-induced peripheral neuropathy are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

chemotherapy-induced neuropathy

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Chemotherapy-induced peripheral neuropathy

Contacts and locations

Locations

  • Abbott Northwestern Hospital

    Minneapolis, Minnesota, 55447, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.